Molecular Diagnosis & Therapy

, Volume 15, Issue 3, pp 159–166

Role of DNA Repair Gene Polymorphisms in the Efficiency of Platinum-Based Adjuvant Chemotherapy for Non-Small Cell Lung Cancer

Authors

  • Juliette Mathiaux
    • Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 916Université de Bordeaux, Institut Bergonié
    • Hôpital du Haut-LévêqueCentre Hospitalier Universitaire de Bordeaux
  • Valérie Le Morvan
    • Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 916Université de Bordeaux, Institut Bergonié
  • Marina Pulido
    • Institut BergoniéINSERM Centre d’Investigation Clinique (CIC)-EC7 et Unité de Recherche et d’Epidémiologie Cliniques
  • Jacques Jougon
    • Hôpital du Haut-LévêqueCentre Hospitalier Universitaire de Bordeaux
  • Hugues Bégueret
    • Hôpital du Haut-LévêqueCentre Hospitalier Universitaire de Bordeaux
    • Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 916Université de Bordeaux, Institut Bergonié
Original Research Article

DOI: 10.1007/BF03256406

Cite this article as:
Mathiaux, J., Le Morvan, V., Pulido, M. et al. Mol Diag Ther (2011) 15: 159. doi:10.1007/BF03256406

Abstract

Background: Cisplatin-based adjuvant treatment of non-small cell lung cancer (NSCLC) has become standard, thanks to the studies that have shown a significant survival advantage. The identification of patients who could benefit from this adjuvant treatment would allow ineffective and toxic administrations to be avoided. Immunohistochemical expression of the excision repair cross-complementation group (ERCC)-1 protein has been associated with response to platinum-based chemotherapy in patients with NSCLC, and some polymorphisms of the genes involved in DNA repair have been shown to be associated with survival in advanced NSCLC.

Objective: The aim of our study was to evaluate the progression-free survival and tolerability of adjuvant treatment with platinum-based chemotherapy in patients with NSCLC, according to common DNA repair gene polymorphisms and ERCC1 expression.

Methods: We investigated the association of three DNA repair gene polymorphisms — Asn118Asn in ERCC1 (rs11615), Lys751Gln in ERCC2 (rs13181), and Asp1104His in ERCC5 (rs17655) — with the progression-free survival of 85 patients treated with platinum-based chemotherapy after surgery for NSCLC.

Results: We did not find significant associations between any of these polymorphisms and progression-free survival, nor did we observe any difference in progression-free survival according to ERCC1 expression.

Conclusion: The previously reported impact of DNA repair gene polymorphisms on platinum-based chemotherapy treatment of advanced NSCLC was not observed in our study in the adjuvant setting.

Copyright information

© Adis Data Information BV 2011